XXXIII: The Claimants’ third pleading point [279]-[282]
XXXIII: The Claimants’ third pleading point [279]-[282]
Mr Fenwick KC submitted that the Banks and Tecnimont were in effect seeking to argue that the Firstline Trust is not in reality a discretionary trust but a bare trust. He said that it was not open to them to advance this argument, because it had not been pleaded.
This submission was incorrect as regards the content of the Defendants’ statements of case. SocGen’s Defence alleged in several places, but most prominently in paragraph 4, that Mr Melnichenko was the ultimate beneficial owner of EuroChem AG through the Firstline Trust. ING’s Defence alleged Mr Melnichenko’s de facto ownership of the Claimants at paragraph 21. Tecnimont’s Defence alleged at paragraph 28 that Mr Melnichenko retained control of the trust assets through Mr Fokin. These were all clear challenges to the Claimants’ case as to the nature of the Firstline Trust.
Furthermore, it was clear that the Claimants expected such challenges to be made at the trial, and were prepared to meet them. Mr Fenwick KC went so far as to acknowledge in his oral opening that, where there was a discretionary trust of this kind, it was incumbent on the party relying on it to meet at least an evidential burden that there was no de facto control, i.e. that the arrangements were genuine.
I therefore reject this third pleading point.
- Heading
- PART A: INTRODUCTION AND PARTIES [1]-[22]
- II: The Claimants [11]-[17]
- III: The Banks and Tecnimont [18]-[20]
- IV: The new Kingisepp plant [21]-[22]
- PART B: THE BONDS AND EUROCHEM NW2’S DEMANDS [23]-[45]
- VI: Designation under Regulation 269 [29]-[33]
- VII: Termination of the Contracts [34]-[37]
- VIII: EuroChem NW2’s demands on the Bonds [38]-[40]
- IX: Rejection of the demands [41]-[45]
- PART C: THE ISSUES AND THE WITNESSES [46]-[98]
- XI: The Claimants’ EuroChem AG witnesses [59]-[66]
- Mr Valters and Mr Solzhenitsyn
- Mr Hechler
- Mr Collishe
- Ms Basyrova
- XII: The Claimants’ EuroChem NW2 witness [67]-[73]
- XIII: The Claimants’ Trust witnesses [74]-[94]
- Mr Fokin
- Mr Noble
- XIV: The Banks’ witnesses [95]-[98]
- PART D: THE FACTS RE OWNERSHIP AND CONTROL [99]-[211]
- The Trusts above EuroChem AG
- The structure from EuroChem AG downwards
- XVI: The ownership structure after sanctions [110]-[123]
- Changes at the level of EuroChem AG
- Changes in directorships
- XVII: Other group structural changes [124]-[144]
- The “Future of EuroChem” memorandum
- The transfers to MCC EuroChem
- The UAE trading cluster
- Changes within EuroChem AG and the EU subsidiaries
- XVIII: Mr Melnichenko’s involvement before March 2022 [145]-[151]
- XIX: The Claimants’ first pleading point [152]-[154]
- XX: The date of the Deed of Retirement [155]-[165]
- XXI: The role of Mrs Melnichenko [166]-[175]
- XXII: Mr Melnichenko’s involvement after March 2022 (1) [176]-[187]
- XXIII: The Claimants’ second pleading point [188]-[197]
- XXIV: Mr Melnichenko’s involvement after March 2022 (2) [198]-[204]
- XXV: The Assignment [205]-[211]
- PART E: REGULATION 269 [212]-[305]
- XXVII: The supplementary EU materials [220]-[225]
- XXVIII: Decisions of the CJEU [226]-[229]
- XXIX: How to interpret Regulation 269 [230]-[240]
- XXX: Article 2(1) [241]-[248]
- XXXI: Article 2(2) [249]-[259]
- XXXII: “Ownership” [260]-[278]
- XXXIII: The Claimants’ third pleading point [279]-[282]
- XXXIV: The MP Bank v Pugachev point [283]-[293]
- XXXV: “Control” [294]-[305]
- PART F: THE NCAS [306]-[347]
- XXXVII: Firewalls and the NCAs [312]-[313]
- XXXVIII: The French NCA: the DGT [314]-[326]
- XXXIX: The Italian NCA: the CSF [327]-[332]
- XL: The Swiss NCA: the SECO [333]-[337]
- XLI: The Cypriot NCA: the SEOK [338]-[341]
- XLII: The Dutch NCA: the BTI [342]-[347]
- PART G: APPLYING REGULATION 269 [348]-[411]
- XLIV: Inferences [360]-[369]
- XLV: Article 2(1) and the Bonds [370]-[378]
- XLVI: The LIA v Maud point [379]-[399]
- XLVII: Article 2(1) and the Assignment [400]
- XLVIII: Article 2(2) and payment to EuroChem NW2 [401]-[403]
- XLIX: Article 2(2) and payment to EuroChem AG [404]-[408]
- L: The pending applications to the DGT and the CSF [409]-[411]
- PART H: REGULATION 833 [412]-[473]
- LII: Are the claims “in connection with” the Contracts? [416]-[429]
- LIII: Are the claims by or on behalf of a Russian entity? [430]-[433]
- LIV: Conclusion on Regulation 833 [434]-[435]
- PART I: THE RULE IN RALLI BROTHERS [436]-[473]
- LVI: The rule in Ralli Brothers [438]-[440]
- LVII: The place of performance under the Bonds [441]-[461]
- LVIII: Licence applications and Article 7 [462]-[465]
- LIX: Public policy [466]-[470]
- LX: Implied term [471]-[472]
- LXI: Conclusion on the rule in Ralli Brothers [473]
- PART J: OTHER ARGUMENTS [474]-[494]
- LXIII: The Bonds’ expiry dates [476]-[478]
- LXIV: Validity of the Assignment [479]-[482]
- LXV: The Assignment and Article 9 [483]-[486]
- LXVI: The sanctioned Russian banks [487]-[491]
- LXVII: ING’s Part 20 claim against Tecnimont [492]-[494]
- Conclusions
![CL-2022-000456 - [2025] EWHC 1938 (Comm)](https://backend.juristeca.com/files/emisores/logo_WAai98v.png)